Your session is about to expire
← Back to Search
CDK4/6 Inhibitor
Ribociclib for Brain Cancer
Phase < 1
Waitlist Available
Led By Nader Sanai, MD
Research Sponsored by Nader Sanai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients ≥ 18 years of age
One prior resection of histologically-diagnosed World Health Organization (WHO) Grade III or IV glioma, or WHO grade II or III meningioma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0.5, 1, 2, 4, 6, 8, and 24 hours post-last 900 mg dosing
Awards & highlights
Study Summary
This trial will test the effects of the drug ribociclib on patients with brain tumors. Patients will take the drug prior to surgery and will be enrolled sequentially (not randomly).
Who is the study for?
Adults with recurrent glioma or meningioma who've had one prior surgery, can sign consent, and meet specific lab criteria. They must not have used ribociclib before, have other recent cancers (except certain skin/cervical cancers), significant heart issues, uncontrolled medical conditions, known hypersensitivity to ribociclib's components or be pregnant/nursing.Check my eligibility
What is being tested?
The trial tests Ribociclib given orally in 5 doses before tumor removal surgery. Patients are enrolled sequentially based on time intervals rather than randomized. The last dose is timed at one of three set periods before the operation.See study design
What are the potential side effects?
Potential side effects of Ribociclib may include blood count changes, liver function alterations, fatigue, nausea and vomiting. It could also affect heart rhythm and cause QT prolongation which is a measure of delayed heart electrical activity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You are 18 years old or older.
Select...
You have had surgery to remove a specific type of brain tumor in the past.
Select...
You must have recovered from any side effects of previous cancer treatments, except for hair loss.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0.5, 1, 2, 4, 6, 8, and 24 hours post-last 900 mg dosing
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0.5, 1, 2, 4, 6, 8, and 24 hours post-last 900 mg dosing
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Brain
CSF Penetration
Plasma Exposure
Trial Design
1Treatment groups
Experimental Treatment
Group I: Administration of ribociclibExperimental Treatment1 Intervention
Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:
Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection
Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection
Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ribociclib
FDA approved
Find a Location
Who is running the clinical trial?
NovartisIndustry Sponsor
1,610 Previous Clinical Trials
2,719,222 Total Patients Enrolled
6 Trials studying Meningioma
231 Patients Enrolled for Meningioma
Ivy Brain Tumor CenterOTHER
10 Previous Clinical Trials
329 Total Patients Enrolled
1 Trials studying Meningioma
72 Patients Enrolled for Meningioma
Barrow Neurological InstituteOTHER
24 Previous Clinical Trials
7,015 Total Patients Enrolled
1 Trials studying Meningioma
72 Patients Enrolled for Meningioma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of being infected with HIV.You have been treated with ribociclib before.You have had another type of cancer within the past 3 years, except for certain types of skin cancer or cervical cancer that has been successfully treated.You have been diagnosed with a heart muscle disease called cardiomyopathy.Your heart's pumping ability, as measured by a special heart test, is less than 50%.You have serious heart rhythm problems or blockages in your heart's electrical system.The tumor does not have a positive Rb status.You currently have a fever or an active infection.You are allergic to any of the ingredients in ribociclib.You have a condition in your stomach or intestines that could make it hard for your body to absorb the study drugs. This includes things like severe ulcers, uncontrolled nausea, vomiting, or diarrhea, and problems with absorbing nutrients from food.You have serious heart problems that are not being controlled.You have had a heart attack, unstable angina, or other serious heart problems within the past 6 months.You have been diagnosed with severe congestive heart failure.You are 18 years old or older.You have a history of heart rhythm problems, or are taking certain medications that can affect your heart rhythm, or have high or low blood pressure.You must have recovered from any side effects of previous cancer treatments, except for hair loss.Evidence from an MRI showing that the disease has come back.For brain tumors, the tissue sample must show specific genetic characteristics related to the RB gene or certain genetic deletions and amplifications.You have had surgery to remove a specific type of brain tumor in the past.You are able to perform daily activities with little or no assistance.You are allergic to peanuts, soy, or lactose.If you have meningioma, the tissue sample must show that the RB protein is present, or genetic testing must show no mutations in the RB gene.Before joining the study, your blood counts, electrolytes, kidney and liver function, and heart's electrical activity must be within a certain range. You also need to be able to swallow the study medication, and if you're taking certain other treatments, you need to stop them for a specific period before starting the study.
Research Study Groups:
This trial has the following groups:- Group 1: Administration of ribociclib
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger